AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01468753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal Insemination
Description: Women will perform vaginal insemination during the fertile period with semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
Study NCT03578016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circle of Security-Parenting
Description: COS-P is a brief, behavioral and insight oriented therapeutic group approach for parents with the aim to promote parental sensitivity and attachment and autonomy in the parent-child relationship. The parents will participate in ten weekly 1,5-hour sessions at the clinic conducted by two COS-certified therapists. Groups will include 4-5 families at a time.
Study NCT03578016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: TAU consists of clinical assessment and treatment.
Study NCT03578016 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: TAU consists of clinical assessment and treatment.
Study NCT04048759 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Remote Low
Description: Participants will attend 40 min remotely delivered group MVPA sessions once a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
Study NCT04048759 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Remote High
Description: Participants will attend 40 min remotely delivered group MVPA sessions 3x a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
Study NCT02663752 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone marrow aspirate
Description: Patients experiencing a hematological response and patients not experiencing a hematological response while on deferasirox treatment received a new bone marrow aspirate in order to investigate the presence of differential gene expression between those two groups
Study NCT02663752 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Deferasirox
Description: Patients are already on commercial deferasirox before entering the study.
Study NCT03841539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Diet consisting of fruits, vegetables, whole grains, low-fat dairy, olive oil, seafood, nuts and beans. It is low in red and processed meats, solid fats and added sugars.
Study NCT03841539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study Supplement
Description: Randomized to take a daily dose of either 2 grams of Omega 3 fatty acids or 2 grams of a Placebo.
Study NCT03841539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study Supplement
Description: Randomized to take a daily dose of either 2 grams of Omega 3 fatty acids or 2 grams of a Placebo.
Study NCT03841539 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat Diet
Description: Diet consisting of fruits, vegetables, whole grains, low-fat dairy, and low-fat protein, with fat contributing no more than 25% of calories.
Study NCT01605032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT01605032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT01605032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT01605032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSCT
Study NCT01605032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous PBSCT
Study NCT03097055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Acupuncture
Description: widely ongoing traditional acupoints in scalp and limbs with traditional deqi manipulation, for stroke patient
Study NCT03097055 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Minimal Acupuncture
Description: non-traditional acupoints in scalp and limbs, with minimal manipulation
Study NCT01436331 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: Services participating in the trial are routine public Community Mental Health Centres (CMHCs), which operate within the Italian National Health Service. Multi-disciplinary teams operating these CMHCs provide a wide range of integrated programmes, including inpatient care, day care, rehabilitation, outpatient care, home visits, 24-hour emergency services, and residential facilities. Standard care for FEP patients generally consists of personalized outpatient psychopharmacological treatment, combined with non-specific supportive clinical management at the CMHC level. Family interventions generally consist of non-specific informal support/educational sessions. Both specialized individual psychotherapeutic interventions for patients (included CBT) and specialized psycho-educational or cognitive-oriented family interventions are usually not provided, due to lack of trained professionals.
Study NCT01436331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU+CBT for pts+Family Intervention+CM.
Description: The experimental treatment package is administered by the CMHC staff, after training and with ongoing supervision by experts. Cognitive-behavioural therapy (CBT) is based on the model developed by Kuipers in 1998 and Garety in 2008. A total of 20-30 CBT sessions per patient will be delivered, with weekly sessions during months 1-3 and fortnightly over the following 6 months. Family Intervention is based on the model proposed by Leff in 1982 and further developed by Kuipers in 2002. It includes a total of 10-15 sessions with each individual family: 6 in months 1-3, and at least 1 session/month in the 6 months afterwards. Every patient/family will have a dedicated Case Manager, who will coordinate all planned interventions. Specific training programs have been developed, with assessment of the staff competence. Detailed Manuals based on international standards have been developed and will be used. Fidelity will be measured at the end of the trial.
Study NCT01995175 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nasal swab sampling
Description: Nasal swab samples will be collected from subjects at each examination visit, if they develop respiratory tract infection symptoms with difficulty in breathing and are called for an examination visit in the study.
Study NCT01995175 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: A single blood sample will be collected from a sub-cohort consisting of the first 2000 enrolled subjects when they are either 2, 4, 6, 12, 18 or 24 months old.
Study NCT01995175 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diary cards
Description: Diary cards will be provided to parents or LARs of the subjects to record RTI/LRTI, wheeze and asthma symptoms.
Study NCT02564445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: All participants will be entered with their teammate into a game that includes points and levels
Study NCT02564445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Share Data with PCP
Description: Weight and step count data will be shared with the participant's primary care physician
Study NCT02564445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on weight
Description: Participants will use a wireless weight scale to weigh-in at home and receive feedback on weight.
Study NCT02564445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on step counts
Description: Participants will use a smartphone application that uses accelerometers within the phone to track step counts and receive feedback on step counts
Study NCT00723190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLONICEL (Clonidine HCl sustained release)
Description: 0.1 mg for 1 week; the dose may be escalated to 0.2 mg/day at week 2, 0.3 mg/day at week 3, and 0.4 mg/day at week 4
Study NCT02650947 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Consumption of capsules containing either 200 mg sucralose (equivalent to diet soda 3 cans) per day for four weeks
Study NCT02650947 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consumption of empty capsule everyday for 4 weeks
Study NCT01741792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.
Study NCT01058759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Study NCT01058759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Enoxaparin
Study NCT03586479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive storybook reading
Description: Children will be taught 30 words prior to, during, and after reading a commercially available storybook by an adult.
Study NCT00467961 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Miltenyi system
Description: Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach.
Study NCT00070018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 250 mg/m\^2, as part of Zevalin regimen
Study NCT00070018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m\^2
Study NCT00070018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 50 mg/m\^2
Study NCT00070018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg
Study NCT00070018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.4 mg/m\^2
Study NCT00070018 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 4000-5000 cGy total
Study NCT00070018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yttrium-90 ibritumomab tiuxetan
Description: 0.4 mCi/kg
Study NCT00070018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Indium-111 ibritumomab tiuxetan
Description: 5 mCi
Study NCT00928941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units/hours.
Study NCT00928941 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: video game
Description: An active control condition (computer game without increasing difficulty) will be implemented for at least 3-4 hours a week for 40 hours.
Study NCT04494763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propanolol
Description: Non-selective Beta-blocker
Study NCT04494763 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive drug
Study NCT00767039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Survanta (beractant)
Description: beractant 4.0 ml/kg/dose (100 mg phospholipid/kg/dose, intratracheal, every 6-12 hours as needed for respiratory distress syndrome for initial and subsequent doses, maximum of 4 doses)
Study NCT00767039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curosurf (poractant)
Description: poractant alfa 2.5 ml/kg/dose initial (200 mg phospholipid/kg), and 1.25 ml/kg/dose subsequent (100 mg/kg/subsequent dose), intratracheal, every 12-24 hours as needed for respiratory distress syndrome, maximum of 3 doses)
Study NCT03191136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1119 300mg
Description: Period 1:a single dose of YHD1119 300mg is administered in fasting condition Period 2:a single dose of YHD1119 300mg is administered in fed condition
Study NCT03191136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1119 300mg
Description: Period 1:a single dose of YHD1119 300mg is administered in fed condition Period 2:a single dose of YHD1119 300mg is administered in fasting condition
Study NCT02782299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Decision aid which is still under revision will include unbiased information to assist is clarifying values and informing patients with distal radius fractures.
Study NCT01491750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GUIDED IMAGERY
Description: DAILY LISTENING TO A GUIDED IMAGERY CD FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
Study NCT01491750 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: DAILY LISTENING TO AN AUDIO BOOK SEGMENT FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
Study NCT01501773 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow stem cell
Description: Autologous bone marrow stem cell have bone marrow aspiration and receive 30-500 million bone marrow mononuclear cells intravenously on the day of randomization.
Study NCT03438734 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regional cerebral oxygen saturation
Description: Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.
Study NCT03438734 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Regional cerebral oxygen saturation
Description: Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.
Study NCT03438734 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral Index (BIS)
Description: The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of BIS decreases with the deepening of anesthesia.
Study NCT03438734 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bispectral Index (BIS)
Description: The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of BIS decreases with the deepening of anesthesia.
Study NCT00875433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: patients to receive continuous oral daily dosing of BIBW 2992
Study NCT01765829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation antipsychotic treatment
Description: Dose reduction until withdrawal
Study NCT01765829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipsychotic treatment
Description: Antipsychotic treatment is not modify during the study, it is administered according to common clinical practice
Study NCT01397786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Phase A: 1-2 mgs/day by mouth, max of 4 wks.~Phase B: 1-4 mgs/day by mouth, up to 52 weeks
Study NCT04048759 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personal Coach
Description: Participants will receive a step counter, access to resources for increasing MVPA, and monthly remote individual support/education.
Study NCT01067625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOGA® System
Description: Formation of restrictive sleeve via transoral gastric stapling for treatment of obesity
Study NCT03541330 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: semi-directive interview
Description: semi-structured interview conducted by a clinical psychologist
Study NCT00843037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles)
Study NCT03500458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: Participants will be asked to increase time in bed at least 1 hour more than baseline
Study NCT02410083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopirin 1
Study NCT02410083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel-Aspirin(co-administration) 1
Study NCT02410083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopirin 2
Study NCT02410083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel-Aspirin(co-administration) 2
Study NCT01310556 — intervention group
Intervention type: OTHER
Intervention: ogtt for patients with coronary artery disease
Description: 75 g OGTT
Study NCT01222377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic surgery
Description: Undergo endoscopic breast surgery
Study NCT01222377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT04631328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Growing Together
Description: Growing Together is a suite of free, online research-informed professional development modules to help early childhood educators promote deeper family engagement and enrich teacher-parent interactions.
Study NCT00707876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferumoxytol
Description: Dose 1 versus non-contrast MRA
Study NCT00707876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferumoxytol
Description: Dose 2 versus non-contrast MRA
Study NCT00707876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferumoxytol
Description: Dose 3 versus non-contrast MRA
Study NCT02106416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: Simultaneous PET/MRI (3T system)
Study NCT03203928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Intervention for Women with ADHD
Description: The intervention will run for 7 weeks and consist of the following 1-hour sessions. Each intervention session will be facilitated by two CUMC occupational therapy students in each participant's home environment (or another environment of the participant's choosing such as the work or school environment).~Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments.
Study NCT03160001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with active RA and receive Etanercept for 8 weeks.: Placebo lactose 500mg cap twice daily
Study NCT03160001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Patients with active RA and receive etanercept with niclosamide cap 500mg twice daily orally as adjuvant therapy for 8 weeks
Study NCT03160001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50mg weekly
Study NCT03160001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etanercept
Description: Etanercept 50mg weekly
Study NCT02237209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV LID ΔM2-2 Vaccine
Description: 10\^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
Study NCT02237209 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
Study NCT06011161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Relationship Checkup (BRC)
Description: The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status.
Study NCT04489381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
Study NCT04489381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets administered orally twice daily with food for 5 days
Study NCT04489381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin Super B-Complex
Description: Vitamin Super B-Complex administered orally twice daily to maintain the blind
Study NCT04489381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Super B-Complex
Description: Vitamin Super B-Complex administered orally twice daily to maintain the blind